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a 26-week, randomized, clinical trial in 456 patients with type 2 diabetes failing treat-
ment with oral antidiabetic agents (OAD) was performed to compare EQW to insulin 
glargine. EQW and insulin glargine were associated with (LS) mean decreases in HbA1c 
(−1.47% and −1.31%), decreases in systolic blood pressure (−3.03 mmHg and 
−0.63 mmHg), and changes in body weight (−2.6 kg and +1.4 kg) from baseline, respec-
tively. METHODS: The published and validated CORE Diabetes Model (CDM) was used 
to project clinical outcomes over patient lifetimes using the trial data. The model simulates 
disease progression by combining 15 Markov-based submodels to determine the occur-
rence and time to onset of diabetes-related complications, life-years gained, and quality-
adjusted life-years (QALYs). Standard CDM utility values for diabetes-related 
complications and weight were included in the model. a discount rate of 3.5% was applied. 
RESULTS: Treatment with EQW compared to insulin glargine was associated with a 
higher life expectancy (11.91 vs. 11.81 years) and quality-adjusted life expectancy 
(8.019 vs. 7.846 QALYs). The cumulative incidence of all diabetes-related complica-
tions was lower for EQW compared to glargine except for stroke and amputation due 
to recurrent foot ulcer: congestive heart failure (31.25% vs. 32.44%), stroke (29.61% 
vs. 29.50%), myocardial infarction (20.50% vs. 21.16%), angina (15.73% vs. 
16.06%), peripheral vascular disease (12.61% vs. 12.73%), amputation recurrent 
ulcer (1.22% vs. 1.19%). Moreover, EQW was associated with a longer mean time 
to onset of ﬁ rst complication versus glargine (4.79 vs. 4.59 years). CONCLUSIONS: 
Long-term projections based on the ﬁ ndings of a recent randomized controlled trial 
indicate that EQW is likely to improve life expectancy and quality-adjusted life expec-
tancy, reduce complication rates, and delay the time to onset of diabetes-related 
complications compared with insulin glargine.
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OBJECTIVES: New classes of antidiabetic medications have been introduced, but 
details of their use are not well known. In Germany, several measures have been 
undertaken to limit the usage of analogues in T1D and T2D patients. The aim was 
to assess the usage patterns of short acting (SA) and basal analogue (BA) insulin in 
primary care in Germany compared to UK and France. METHODS: Computerized 
patient data from general medicine practices (IMS Disease Analyzer, 01/2007 to 
12/2009) throughout Germany, UK, and France have been analyzed on treatment rates 
and outcome. RESULTS: In 2009 10,792 insulin patients in France, 20,244 in UK, 
and 103,238 in Germany were analyzed. The dominance of BA and SA insulins is 
differing by country and diabetes type (Germany: SA insulins in T2D 40.8% vs. UK 
95.8% and France 92.3%). Treatment of T1D with analogous insulins is in general 
higher compared to T2D (Germany: 56.1% BA in T2D vs. 66.3% in T1D; 40.8% SA 
in T2D vs. 74.3% in T1D). Usage share of analogous insulins increased over the 3-year 
period in all three countries (T2D patients, Germany: BA usage 47.6% in 2007 vs. 
56.1% in 2009; UK: 78.0% in 2007 vs. 83.0 % in 2009, France 82.2% in 2007 vs. 
88.5% in 2009). The analysis of HbA1c values in UK and Germany revealed a higher 
share of patients with uncontrolled HbA1c values (>7.0) for population treated with 
analogues (70.8% in Germany) vs. human insulin (68.4%) vs. OAD (42.9%). Increase 
hints to high unmet medical need in human insulin usage and shift to analogues. 
CONCLUSIONS: Despite several health political measures in Germany favoring 
human insulins over analogues, the prevalence of both SA and BA insulin usage for 
diabetes patients continuously increased in Germany in line with UK and France from 
2007 to 2009 to meet medical need by higher analogue usage.
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OBJECTIVES: Newer long-acting insulin analogs have shown to result in several treat-
ment improvements if compared with NPH insulins. Promising results from clinical trials 
require conﬁ rmation from observational settings reﬂ ecting potential “real-life” beneﬁ ts. 
Therefore, the current study aimed to evaluate trends in prescribing (uptake), treatment 
adherence, and costs of (newer) insulin analogs (e.g., insulin detemir and insulin 
glargine). METHODS: A drug-utilization analysis was conducted based on using daily-
practice prescription data from IADB.nl (one of the databases available in the Mondri-
aan infrastructure), a dispensing database of 50 pharmacies, covering a Dutch population 
of 500,000. Drug-utilization data were collected for a 7-year period (2000–2007). All 
patients that received at least one prescription of an insulin analog—deﬁ ned following 
the “Anatomical Therapeutical Classiﬁ cation” (ATC) as “A10A”—were included for 
this study. The prevalence and incidence of insulin use were both presented per 1000 
population. Survival analysis was conducted to calculate the persistence on different 
insulin analogs. RESULTS: Preliminary results show a fast increase in the proportion 
of patients using the newer long-acting insulin analogs with 7% in 2003 to over 30% 
in 2006. Among patients initiating these newer insulin analogs, use of insulin glargine 
is more than two times higher compared to use of insulin detemir (507 vs. 190 starters 
in 2006). Patients that initiated treatment with long-acting insulin analogs were signiﬁ -
cantly more adherent to insulin glargine compared to insulin detemir (exact ﬁ gures will 
be presented during the presentation). CONCLUSIONS: Current preliminary results 
show an increase in use of long-acting insulin analogs. Of these analogs, insulin glargine 
is most often initiated and seems to be well-received by patients. Further results will be 
presented based on a longer follow-up period including differences in HbA1c level 
dependent dosing and trends in cost development for insulin analogs over time. Also, 
the potential feature of “channelling” will be investigated.
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OBJECTIVES: Diabetic peripheral neuropathic pain (DPNP) is often managed using 
opioids which are subject to tolerance and dependence issues. Newer classes of medica-
tions have been approved for DPNP; however, published ﬁ ndings assessing utilization 
of opioids following treatments with these agents are limited. This retrospective cohort 
study compared the subsequent use of opioids between commercially insured DPNP 
patients initiating duloxetine treatment versus other standard of care (SOC) therapies. 
METHODS: DPNP patients aged 18 to 64 who initiated duloxetine or other SOC 
treatments (tricyclic antidepressants, venlafaxine, gabapentin, pregabalin) between 
March 1, 2005 and December 31, 2005 were selected. Initiation was deﬁ ned as a 
90-day period without available study medication. The initial dispense date for the 
study medication was deﬁ ned as the index date. Selected patients had no opioid pill 
coverage during the 90 days prior to the index date, and no depression, neuralgia, or 
epilepsy diagnosis in the 12-month pre-index period. Duloxetine and SOC patients 
were matched via propensity scoring (1:1 ratio), controlling for demographics, comor-
bidities, prior health-care utilization and costs, and prior medication history. Opioid 
utilization and health-care costs over the 12-month post-index period were compared 
between study cohorts. RESULTS: A total of 113 patients in each of the duloxetine 
and SOC cohorts were matched. Duloxetine-treated patients were less likely to use 
any opioids versus SOC-treated patients (52.2% vs. 79.6%, P < 0.01) over the 
12-month post-index period. Compared with SOC patients, duloxetine patients had, 
on average, 110 days delay in opioid use, two fewer prescriptions dispensed, 32 fewer 
days on opioids, and 2064 mg lower morphine equivalent dosage (all P < 0.01) over 
the 12-month post-index period. Duloxetine patients also had signiﬁ cantly lower total 
($19,408 vs. $30,470, P < 0.01) and outpatient costs ($7,606 vs. $15,272, P < 0.01). 
CONCLUSIONS: Among commercially insured DPNP patients, duloxetine treatment 
appears to be associated with delayed and reduced opioid utilization and lower health-
care costs than SOC therapies.
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BACKGROUND: Despite the progress of clinical trials, clinicians and decision-mark-
ers often lack knowledge on how to better promote health-care delivery to patients 
with T2DM in clinical practice. Outcome research studies can provide effectiveness 
and economic analysis in actual practice in order to improve clinical performance. 
OBJECTIVES: To describe the resources used and the costs associated with outpatient 
treatment of T2DM in the Brazilian PHS. METHODS: This is a cross-sectional analy-
sis of 383 T2DM outpatients treated in ﬁ ve cities by various health plans. Data were 
collected using info from the previous year by interviewing patients using a validated 
questionnaire complemented by medical chart review. Direct costs included expenses 
associated with medications, diagnostic tests, procedures, blood glucose test strips, 
and health professional visits. Nonmedical direct costs included expenses with diet 
products. Indirect costs were not assessed. RESULTS: The group had a mean age of 
60.5 ± 9.6 years and a mean duration of diabetes of 12.2 ± 8.75 years. Annual out-
patient cost of T2DM care was R$10,645.78 per patient, being R$9,534.58 for direct 
medical costs and R$1,111.20 for nonmedical costs. Costs escalated as duration of 
diabetes increased (R$8796.68 per patient <9 years vs. R$13,231.74 >19 years of 
disease; P = 0.05). Those patients with associated microvascular and macrovascular 
complications (n = 18%) have higher costs (R$15,755.12 per patient) compared to 
those with microvascular (R$9178.38 per patient; n = 32.4%), macrovascular 
(R$8726.13 per patient; n = 8.1%), or no complications (R$8246.53 per patient; n = 
41.5%). Annual per patient expenses included medications (R$5542.94), blood 
glucose home monitoring (R$1,014.62), private health professional visits (R$4,264.04), 
and diet products (R$1,111.20). Health plans expenses per year were due to exams/
procedures (R$588.02 per patient), medications co-payment (R$1,029.00 per patient), 
and health professional visits (R$734.12 per patient). CONCLUSIONS: The outpa-
tient care costs assessed reveal that diabetes poses a serious social and economic 
burden to patients and to Brazilian PHS.
